Virtual Library
Start Your Search
Y. Guo
Author of
-
+
P1.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 209)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.02-026 - For NSCLC with T3 (Central) Disease, Sleeve Lobectomy or Pneumonectomy? (ID 38)
09:30 - 09:30 | Author(s): Y. Guo
- Abstract
Background:
Pneumonectomy has traditionally been the treatment of choice for central lung tumors for which the alternative is sleeve lobectomy. The aim of this study was to compare early and long-term results after sleeve lobectomy and pneumonectomy in focusing on T3 central non-small cell lung cancer (NSCLC).
Methods:
Patients who underwent sleeve lobectomy (n = 58) or pneumonectomy (n = 42) were retrospectively analyzed. For bias reduction, these 100 patients had been selected according to the following criteria: (1) tumor located in the main bronchus less than 2 cm distal to the carina, (2) there was no N2 disease, (3) no induction therapy was applied, (4) a complete resection was achieved.
Results:
Sleeve lobectomy and pneumonectomy patients have had comparable mean ages, gender distribution, mean forced expiratory volume in 1 second, stage and tumor grade. Postoperative mortality (3.4% vs 4.8%, p = 1.0) and morbidity (41% vs 38%, p = 0.74) were similar between the two groups. Recurrences occurred in 48% of patients after sleeve lobectomy and in 31% of those after pneumonectomy (p = 0.08). The 5-year survival after sleeve lobectomy (64.8%) and pneumonectomy (61.4%) was not significantly different (p = 0.20). Multivariable survival analysis showed that there were no independent prognostic factors.
Conclusion:
Sleeve lobectomy does not compromise survival for NSCLC with T3 central disease compared with pneumonectomy. It is an adequate oncologic resection and should be treated as the first line intervention whenever complete resection can be achieved.
